Cantor Fitzgerald Starts Aytu Biosciences (AYTU) at Overweight

Cantor Fitzgerald analyst Jennifer Kim initiates coverage on Aytu Biosciences (NASDAQ: AYTU) with an Overweight rating and a price target of $11.00.

The analyst commented, "We are initiating coverage of AYTU shares with an Overweight rating and a 12-month PT of $11 using DCF analysis. Through a strategy of in-licensing and acquisition-based transactions, AYTU has built a highly diversified, growing portfolio of commercial Rx and consumer health products, with a focus on pediatrics. We believe AYTU's transformation remains underappreciated and expect solid execution in 2021+ and upwards earnings estimate revisions to drive shares higher. Things to look for include: 1) sales growth and G&A synergies across business segments; 2) business development to build a novel, late-stage pipeline focused on pediatrics; and 3) progress in non-pediatric pipeline assets (e.g., Healight, NT0502)."

For an analyst ratings summary and ratings history on Aytu Biosciences click here. For more ratings news on Aytu Biosciences click here.

Shares of Aytu Biosciences closed at $7.71 yesterday.

You May Also Be Interested In

• UPDATE: Loop Capital Starts Coinbase Global Inc. (COIN) at Buy, 'Lots of Runway Before Takeoff'
• UPDATE: Goldman Sachs Starts Editas Medicine (EDIT) at Sell, Cautious on Lead Drugs
• UPDATE: Goldman Sachs Starts Apellis Pharmaceuticals (APLS) at Buy